Haemonetics (HAE) Shares Outstanding (Diluted Average) (2009 - 2026)

Haemonetics' Shares Outstanding (Diluted Average) history runs 18 years deep, the most recent figure standing at $47.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) fell 6.65% year-over-year to $47.4 million; the TTM figure through Mar 2026 stood at $47.4 million (down 6.65% YoY), while the FY2026 annual figure was $47.4 million, down 6.65% from the prior year.
• Shares Outstanding (Diluted Average) was $47.4 million for Q1 2026 at Haemonetics, down from $47.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $51.7 million in Q3 2022 to a low of $47.4 million in Q1 2026.
• Historically, Shares Outstanding (Diluted Average) has averaged $50.5 million across 5 years, with a median of $51.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) advanced 1.46% in 2022, then slipped 6.98% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $51.2 million in 2022, then grew by 0.34% to $51.4 million in 2023, then retreated by 1.47% to $50.6 million in 2024, then fell by 5.87% to $47.7 million in 2025, then retreated by 0.66% to $47.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $47.4 million (Q1 2026), $47.7 million (Q4 2025), and $47.7 million (Q3 2025), per Business Quant data.